KeyBanc raised the firm’s price target on ResMed (RMD) to $266 from $251 and keeps an Overweight rating on the shares following the Q1 earnings report. KeyBanc was encouraged by the broad ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

RBC Capital raised the firm’s price target on ResMed (RMD) to $232 from $224 and keeps a Sector Perform rating on the shares. The company reported a strong Q1 result with double digit revenue ...

Over the last year, Resmed share price has been traded in a range of 80.58, hitting a high of 260.00, and a low of 179.42.

Pre-earnings options volume in ResMed (RMD) is 3.5x normal with puts leading calls 7:5. Implied volatility suggests the market is anticipating a move near 6.9%, or $16.63, after results are released.

Commissions do not affect our editors' opinions or evaluations. The price of gold today, as of 8:17 am ET, was $2,743 per ounce. That’s up 0.16% from yesterday’s gold price of $2,739.

Although the Resmed share price is not as good value as it was six months ago, the ASX healthcare share seems to have a promising future.

The Sony Cyber-Shot RX100 II has been available since July 2013 for a list price of US$750. That's a modest US$100 increase over list pricing for the original Sony RX100, which continues to be ...

The Olympus E-M10 II became available in September 2015 for an MSRP of $799 with the EZ 14-42mm kit lens, and a body-only MSRP of $649, currently selling for a body-only street price of $599.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea ...